MedDataX Logo

Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome

NCT ID: NCT06373926

Last Updated: 2025-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-05

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Annexin A2 (ANXA2), an endothelial cell receptor for plasminogen and tissue plasminogen activator, plays a pivotal role in regulation of fibrinolysis in vitro and in vivo and has been identified as a new autoantigen in antiphospholipid syndrome (APS). ANXA2 can exist as a monomer or a heterotetrameric complex with S100A10 protein. The aim of this study was to evaluate the cell membrane expression of ANXA2 on circulating monocytes in APS by flow cytometry. Several pathogenic mechanisms are involved in APS such as activation of endothelial cells, platelets and monocytes, inhibition of the natural anticoagulant protein C/protein S pathway, activation of the complement system and also impairment of fibrinolysis. Annexin A2 which hits binding partner S100A10, ANXA2 forms a cell surface complex that regulates generation of plasmin. ANXA2 is involved in the pathogenesis of APS-associated through several possible mechanisms. Human peripheral blood monocytes represent the major circulating ANXA2-expressing cell and ANXA2-mediated assembly of plasminogen and tissue activator of plasminogen (tPA) on monocyte/macrophages contributes to plasmin generation. Thus the investigators could suppose that decrease of cell membrane expression of ANXA2 on circulating monocytes represent a new pathogenic mechanism in APS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Proteins of the Contact Activation System

NCT02785718

Factor XI Deficiency Factor XII Deficiency
UNKNOWN NA

An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

NCT00945906

Factor XIII Deficiency
COMPLETED PHASE3

An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency

NCT02427217

Congenital Fibrinogen Deficiency
COMPLETED

A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

NCT05265286

Severe Hemophilia A
COMPLETED PHASE2

Cooperative Study of Factor VIII Inhibitors

NCT00000582

Blood Coagulation Disorders Hematologic Diseases Hemophilia A +1 more
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Antiphospholipid Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

case

APS patients

Group Type EXPERIMENTAL

blood withdrawal

Intervention Type BIOLOGICAL

blood withdrawal

control

healthy individuals

Group Type ACTIVE_COMPARATOR

blood withdrawal

Intervention Type BIOLOGICAL

blood withdrawal

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood withdrawal

blood withdrawal

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* APS patients who fulfilled the revised criteria for APS

Exclusion Criteria

* Patients less than 18 years old
* Solid and hematological malignancies
* Other autoimmune diseases
* Cirrhosis
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire, Amiens

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Amiens

Amiens, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Valéry Salle, MD

Role: CONTACT

[email protected]
03 22 66 82 30

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Valéry SALLE, MD

Role: primary

[email protected]
+33 3 22 66 82 30

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PI2019_843_0010

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
NCT06142552 RECRUITING PHASE3
Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors
NCT02554526 UNKNOWN
A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
NCT04864743 COMPLETED PHASE1
Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency
NCT02470871 COMPLETED PHASE1
Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders
NCT04548791 TERMINATED PHASE1/PHASE2
Severe Pregnancy Complications Are Associated With Elevated Factor VIII Plasma Activity
NCT00573118 UNKNOWN
Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors
NCT00221195 COMPLETED PHASE2/PHASE3
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
NCT02053792 COMPLETED PHASE3
Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures
NCT00618098 COMPLETED PHASE3
A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip
NCT04592692 UNKNOWN PHASE2
Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults
NCT06665828 COMPLETED PHASE1
Study Evaluating The Safety Of Xyntha In Usual Care Settings
NCT00765726 TERMINATED PHASE4
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers
NCT05102136 COMPLETED PHASE1
Pre-clinical Models for Mesenchymal Stem Cell Therapy in Hemophilic Arthropathy
NCT05187936 UNKNOWN
Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors
NCT02020369 COMPLETED PHASE3
A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
NCT00885742 COMPLETED PHASE3
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
NCT04072237 COMPLETED PHASE1
An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.
NCT04456387 COMPLETED PHASE3
Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
NCT00306670 TERMINATED PHASE2/PHASE3
Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B
NCT01233440 COMPLETED PHASE1
A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
NCT01496274 COMPLETED PHASE2/PHASE3
First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients
NCT01191372 TERMINATED PHASE1
Pharmacokinetics and Safety of Roledumab in RhD-negative Pregnant Women Carrying an RhD-positive Foetus
NCT02287896 COMPLETED PHASE2
Hemophilia and Bone Metabolism: Study of Monocytic Populations and Inflammatory Proteins
NCT04206033 COMPLETED
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
NCT04563520 RECRUITING PHASE3